VREX vs PHG vs POSC Stock Comparison

Varex Imaging, Koninklijke Philips and Positron Prices as of Oct 26, 2026 Peers: Industry group
VREX Varex Imaging Corp
$18.41 -0.2% 1M +53.5% 1Y
Market cap
$775.69M
P/E
35.1x
Revenue (TTM)
$865.00M
Div. yield
–
Diagnostic Equipment Healthcare
1 win
PHG Koninklijke Philips Nv
$26.56 +6.4% 1M -7.9% 1Y
Market cap
$25.08B
P/E
13.6x
Revenue (TTM)
$20.60B
Div. yield
–
Diagnostic Equipment Healthcare
7 wins
POSC Positron Corp
$1.70 -8.1% 1M +9.7% 1Y
Market cap
$55.19M
P/E
–
Revenue (TTM)
$462.27K
Div. yield
–
Diagnostic Equipment Healthcare
3 wins

Head to Head

11 decided of 12

Koninklijke Philips leads on 7 of the 12 questions below (Koninklijke Philips 7, Positron 3, Varex Imaging 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionVREXPHGPOSCLeader
Larger companyMarket capitalisation $775.69M $25.08B $55.19M PHG
Cheaper on earningsLower P/E, profitable companies only 35.1x 13.6x -11.3x PHG
Cheaper on forward earningsLower price / next fiscal year consensus EPS 21.2x 13.4x — PHG
Faster revenue growthRevenue growth, trailing twelve months +5.3% +6.1% +202.2% POSC
More profitableNet margin, trailing twelve months 2.6% 8.9% -1,060.5% PHG
Better return on capitalReturn on invested capital 6.9% 11.5% — PHG
Less leveragedLower net debt / EBITDA 2.5x 1.8x -0.3x POSC
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +53.5% -7.9% +9.7% VREX
Better 5-year returnAnnualised price return, 5 years -7.0%/yr -10.8%/yr +23.2%/yr POSC
Less volatileAnnualised volatility, 1 year 57.6% 28.8% 86.9% PHG
Higher overall scoreMean of the five percentile scores vs peers 51/100 80/100 13/100 PHG

Percentile Scorecard

VREXPHGPOSC

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisVREXPHGPOSC
Valuation 87 #31 of 228 98 #6 of 228 21 #181 of 228
Growth 23 #170 of 221 96 #11 of 221 18 #181 of 221
Profitability 66 #71 of 208 96 #10 of 208 4 #200 of 208
Financial Health 41 #141 of 239 31 #166 of 239 4 #229 of 239
Shareholder Returns 36 #88 of 137 79 #29 of 137 18 #112 of 137
Overall 51 80 13
  • VREX ranked among 248 companies in Medical Devices and Diagnostics
  • PHG ranked among 248 companies in Medical Devices and Diagnostics
  • POSC ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodVREXPHGPOSCSPY
1 month -0.2%+6.4%-8.1% -0.8%
3 months +67.7%+6.2%+8.3% +3.5%
6 months +44.8%-3.6%-11.9% +7.0%
Year to date +58.0%-1.9%+1.8% +12.2%
1 year +53.5%-7.9%+9.7% +13.0%
3 years +6.4%+43.6%+36.0% +86.3%
3 years, per year +2.1%+12.8%+10.8% +23.1%
5 years -30.3%-43.6%+183.3% +68.6%
5 years, per year -7.0%-10.8%+23.2% +11.0%
10 years —-11.6%+5,566.7% +258.0%
10 years, per year —-1.2%+49.7% +13.6%

Risk

MeasureVREXPHGPOSCSPY
Volatility, 1Y 57.6%28.8%86.9% 12.7%
Downside volatility, 1Y 50.0%28.8%87.5% 12.7%
Beta vs S&P 500, 1Y 1.110.810.28 1.00
Return / volatility, 1Y 0.93-0.270.11 1.02
Max drawdown, 5Y -78.8%-75.6%-65.6% -25.4%
From 52-week high -0.9%-19.3%-33.6% -1.8%
52-week high $18.58$32.91$2.56 $779.14
52-week low $9.32$23.81$1.31 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleVREXPHGPOSC
P/E now vs peer median 35.1xmedian 30.6x 13.7xmedian 30.6x -11.4xmedian 30.6x
P/S now vs peer median 0.9xmedian 3.0x 1.2xmedian 3.0x 120.8xmedian 3.0x
EV/EBITDA now vs peer median 10.1xmedian 17.5x 8.1xmedian 17.5x -12.1xmedian 17.5x
P/FCF now vs peer median -38.4xmedian 23.3x 5.9xmedian 23.3x -13.4xmedian 23.3x
P/B now vs peer median 1.5xmedian 2.4x 2.0xmedian 2.4x -84.5xmedian 2.4x
PEG now vs peer median -9.15median 0.87 0.32median 0.87 —median 0.87

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsVREXPHGPOSC
Revenue $865.00M $20.60B $462.27K
Gross profit $296.90M $16.03B -$1.33M
Operating income $72.20M $2.65B -$4.82M
Net income $22.40M $1.39B -$4.90M
Free cash flow -$20.20M $4.34B -$4.16M
R&D $91.40M $2.00B –
EPS (diluted) $0.52 $1.91 $-0.15
Cash & equivalents $99.20M $2.04B $357.17K
Total debt $347.10M $9.51B $2.00M
Shares (diluted) 42.60M 962.50M 32.85M
Enterprise value $307.49M $14.19B $47.91M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricVREXPHGPOSC
P/E 35.1x 13.7x -11.4x
P/FCF -38.4x 5.9x -13.4x
P/Operating cash flow 68.7x 9.6x -13.4x
P/S 0.9x 1.2x 120.8x
P/B 1.5x 2.0x -84.5x
P/Tangible book 1.6x 2.5x -84.5x
EV/EBITDA 10.1x 8.1x -12.1x
EV/EBIT 14.2x 12.4x -11.9x
EV/Revenue 1.2x 1.6x 124.3x
EV/FCF -50.7x 7.6x -13.8x
EV/Operating cash flow 90.6x 12.4x -13.8x
PEG (3Y EPS CAGR) -9.15 0.32 –

Growth

14 metrics
MetricVREXPHGPOSC
Revenue growth (1Y) 5.3% 6.1% 202.2%
Revenue CAGR (3Y) -1.2% 2.3% –
Gross profit growth (1Y) 6.1% 82.4% -15.2%
Gross profit CAGR (3Y) 1.2% 6.7% –
Operating income growth (1Y) 297.8% 121.3% -17.5%
Operating income CAGR (3Y) -2.3% 52.0% –
Net income growth (1Y) 116.7% 293.5% -18.0%
Net income CAGR (3Y) -9.2% 35.6% –
EPS growth (1Y) 116.1% 539.4% -12.5%
EPS CAGR (3Y) -3.8% 42.2% –
Operating cash flow growth (1Y) -81.1% 116.7% -17.0%
Operating cash flow CAGR (3Y) -47.6% 53.6% –
Free cash flow growth (1Y) -155.5% 54.2% -17.0%
Free cash flow CAGR (3Y) -33.5% 45.6% –

Profitability

14 metrics
MetricVREXPHGPOSC
Gross margin 34.3% 77.8% -288.1%
EBITDA margin 11.7% 19.8% -1,030%
Operating margin 8.3% 12.9% -1,042%
Pretax margin 3.2% 11.9% -1,060%
Net margin 2.6% 8.9% -1,060%
FCF margin -2.3% 21.1% -900.4%
Operating cash flow margin 1.3% 12.9% -900.4%
Return on equity 4.5% 12.7% –
Return on assets 2.1% 5.4% -216.9%
Return on invested capital 6.9% 11.5% –
Return on capital employed 8.0% 11.8% -61,094%
Asset turnover 0.8x 0.7x 0.2x
Cash conversion (OCF / net income) 0.5x 1.9x 0.8x
Stock comp / revenue 1.7% 0.7% –

Financial Health

11 metrics
MetricVREXPHGPOSC
Debt / assets 31.6% 31.2% 115.8%
Debt / equity 0.7x 0.7x -3.0x
Net debt / EBITDA 2.5x 1.8x -0.3x
Debt / FCF -17.2x 2.2x -0.5x
Liabilities / assets 53.6% 57.1% 138.2%
Equity / assets 46.4% 42.9% -38.2%
Interest coverage 1.9x 6.2x -43.8x
Current ratio 3.4x 1.3x 0.5x
Quick ratio 1.3x 0.7x 0.2x
Cash ratio 0.5x 0.2x 0.2x
Altman Z-score 2.28 – -114.88

Shareholder Returns

7 metrics
MetricVREXPHGPOSC
Dividend yield – 3.7% –
Net buyback yield -0.4% -0.5% -5.4%
Shareholder yield -0.4% 3.3% -5.4%
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusVREXPHGPOSC
Forward P/E 21.2xFY2026 13.4xFY2026 –
EPS, next fiscal year $0.87FY2026 $1.98FY2026 –
EPS growth, next FY -3.3%FY2026 +6.5%FY2026 –
EPS growth, the year after +14.9% -10.1% –
Revenue, next fiscal year $829.68MFY2026 $21.63BFY2026 –
Revenue growth, next FY -1.8%FY2026 +1.8%FY2026 –
Revenue growth, the year after +2.3% -8.2% –

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersVREXPHGPOSC
Held by institutions 95.2% 5.4% –
Institutions holding 186 363 –
Change in shares held, QoQ -2.7% +0.8% –
Institutions buying 98 266 –
Institutions selling 58 76 –
Buyers to sellers 1.69 3.50 –

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

VREXPHGPOSC
VREX 1.00 0.27 -0.03
PHG 0.27 1.00 0.00
POSC -0.03 0.00 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, VREX, PHG and POSC?

Koninklijke Philips (PHG) is the largest by market capitalisation: Varex Imaging (VREX) $775.69M, Koninklijke Philips (PHG) $25.08B, Positron (POSC) $55.19M.

Which stock is cheaper, VREX, PHG and POSC?

Koninklijke Philips (PHG) trades on the lowest price-to-earnings ratio (Varex Imaging (VREX) 35.1x, Koninklijke Philips (PHG) 13.6x, Positron (POSC) -11.3x). On next year's consensus earnings, Koninklijke Philips (PHG) is cheapest (Varex Imaging (VREX) 21.2x, Koninklijke Philips (PHG) 13.4x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Positron (POSC) grew revenue fastest over the trailing twelve months: Varex Imaging (VREX) +5.3%, Koninklijke Philips (PHG) +6.1%, Positron (POSC) +202.2%.

Which company is more profitable?

Koninklijke Philips (PHG) has the highest net margin (Varex Imaging (VREX) 2.6%, Koninklijke Philips (PHG) 8.9%, Positron (POSC) -1,060.5%). On return on invested capital, Koninklijke Philips (PHG) leads (Varex Imaging (VREX) 6.9%, Koninklijke Philips (PHG) 11.5%).

Which stock has performed better?

Over the past year Varex Imaging (VREX) returned the most: Varex Imaging (VREX) +53.5%, Koninklijke Philips (PHG) -7.9%, Positron (POSC) +9.7%. Over five years, Positron (POSC) compounded fastest (Varex Imaging (VREX) -7.0%/yr, Koninklijke Philips (PHG) -10.8%/yr, Positron (POSC) +23.2%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Koninklijke Philips (PHG) has been the steadiest (Varex Imaging (VREX) 57.6%, Koninklijke Philips (PHG) 28.8%, Positron (POSC) 86.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, VREX, PHG and POSC?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Koninklijke Philips (PHG) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.